Monday, November 25, 2024

Life Sciences

Firefly Bio
-- Transformational degrader antibody conjugate company backed by leading syndicate including founding investor Versant Ventures, MPM BioImpact, Decheng Capital and Eli Lilly & Company -- Firefly Bio emerged from stealth mode with a $94 million Series A financing co-led by founding investor Versant Ventures and by MPM BioImpact alongside Decheng...
Clarius
T-Mode TM AI by Clarius creates a split screen during an exam that displays a colorful anatomical image with labels next to the grayscale ultrasound image Clarius Mobile Health, a global leader in wireless ultrasound solutions, announces T-ModeTM AI, a groundbreaking educational technology to help clinicians who are new to ultrasound advance their image...
VantAI
Collaboration to leverage VantAI's expertise in generative AI and geometric deep learning to identify molecular glues against targets of interest with an option to expand to additional programs VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a leading pharmaceutical company, have entered into a strategic...
Roche
Roche announced that it has entered into an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the terms of this agreement, PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop AI-enabled digital pathology algorithms in the companion diagnostics space. RTD will work...
Enable Medicine
Enable Medicine, a leader in AI for biological research and drug discovery, has announced the appointment of Kamni Vijay as Chief Executive Officer. She succeeds co-founder Sunil Bodapati, who developed Enable Medicine’s strategy and closed Series A financing in 2022. Mr. Bodapati remains Chairman of the Board and will...
BioXcel Therapeutics
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability BioXcel Therapeutics, Inc., a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the U.S. Food...
Revvity
Centralized data science platform streamlines clinical study data management for swift, insight-driven clinical decisions and therapeutic advancements Revvity, Inc. announced that its software and informatics division, Revvity Signals, is unveiling the Signals Clinical solution, a software-as-a-service (SaaS), end-to-end clinical data science platform designed to centralize all clinical trial data, providing fast, actionable...
Saama
Saama, a provider of AI-based solutions that accelerate clinical development and commercialization, announced a newly expanded, multi-year agreement with global biopharmaceutical leader Pfizer to help expedite clinical research. The agreement represents the expansion of a strategic relationship that began in 2020 when Saama and Pfizer entered into a partnership to automate...
Meliora Therapeutics
Meliora Therapeutics, a machine learning therapeutics company developing novel and transformative cancer drugs, announced the promotion of Claudio Chuaqui, Ph.D., to Chief Scientific Officer (CSO), and the appointment of Anand Selvaraj, Ph.D. as Vice President and Head of Cancer Biology. “These leadership updates mark the beginning of a new phase...
Iambic Therapeutics
Advances in AI Platform Provide an Ability to Rapidly Predict, Identify and Design Biomolecular Structures to Accelerate the Pace and Reduce the Cost of Drug Discovery and Development Iambic Therapeutics, a biotechnology company developing novel therapeutics using its unique generative AI discovery platform, announced the publication of research in Nature...